GlobalData on MSN1d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Pharmaceutical Technology on MSN21h
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...
Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...
A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...
Sunitinib Malate Market Sunitinib Malate Market Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Sunitinib Malate - Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback